TheraRadar
← Back
Data updated: May 24, 2026

CELLTRION, INC.

Biotech
ImmunologyOncologyGastroenterology Execution: Good

CELLTRION, INC. is a biotechnology company focused on Immunology, Oncology, Gastroenterology.

2024
Since
1
Drugs
-
Trials
2
New Drugs (2yr)

CELLTRION, INC. at a Glance

  • Fast trial execution (14 months median completion)

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

STEQEYMA
Immunology
Approved 2024

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

STEQEYMA BLA
2025-04-30
ustekinumab-stba
1. INDICATIONS AND USAGE STEQEYMA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1. Plaque Psoriasis (PsO) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2. Psoriatic Arthritis (PsA) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3. Crohn's Disease (CD) STEQEYMA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. 1.4. Ulcerative Colitis STEQEYMA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
STEQEYMA BLA
2024-12-17
ustekinumab-stba
1. INDICATIONS AND USAGE STEQEYMA is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis (PsO), who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) 1.1. Plaque Psoriasis (PsO) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. 1.2. Psoriatic Arthritis (PsA) STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. 1.3. Crohn's Disease (CD) STEQEYMA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. 1.4. Ulcerative Colitis STEQEYMA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Immunology 57%
0 drugs Phase 3: 15 Phase 1: 4
Oncology 27%
0 drugs Phase 3: 7 Phase 1: 2
Gastroenterology 7%
0 drugs Phase 3: 1 Phase 2: 1 Phase 1: 2
Cardiovascular 4%
0 drugs Phase 3: 1 Phase 1: 1
Infectious Disease 4%
0 drugs Phase 2: 1 Phase 1: 3

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

24
Phase 3
2
Phase 2
12
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • STEQEYMA leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 23/30 completed
  • • Speed: 14 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges